1. India Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited

NNSE:BALAXI
21.00
INR
-0.10
(-0.47%)
0.46EPS
52.48P/E
1.32BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.08
0.03
- -
- -
8.94
12.13
46.27
55.88
67.06
46.88
52.99
48.94
52.64
Basic EPS, GAAP
0.07
-0.05
-0.11
-0.51
1.29
1.62
7.63
9.53
9.16
-0.46
4.54
0.26
0.46
Free Cash Flow per Basic Share
0.14
-0.03
-0.09
-0.45
-0.99
-3.78
-0.51
1.47
-1.32
0.64
-10.28
-8.58
- -
Dividend per Share
0.05
0.07
- -
- -
- -
- -
- -
- -
0.1
- -
- -
- -
- -
Book Value per Share
0.02
1.64
1.53
1.02
2.32
5.55
13
22.63
35.92
36.96
41.98
45.12
- -
Tangible Book Value per Share
0.02
1.64
1.53
1.02
2.32
5.55
12.74
17.81
30.79
32.02
37.01
39.08
- -
Basic Weighted Avg Shares
15
15
15
15
15
38
50
50
50
51
55
55
53
Sales/Revenue/Turnover
1
- -
- -
- -
136
456
2,313
2,794
3,364
2,413
2,926
2,702
2,801
Operating Margin (%)
35.04
-99.69
- -
- -
12.02
18.07
18.34
18.01
16.54
18.98
12.44
2.77
2.32
Depreciation Expense
- -
- -
- -
- -
- -
- -
3
5
18
21
19
22
25
Net Income, GAAP
1
-1
-2
-8
20
61
381
477
460
-24
251
14
24
Effective Tax Rate (%)
30.44
- -
- -
- -
19.41
30.59
13.97
12.59
19.25
218.44
12.55
73.23
62.58
Profit Margin (%)
82.71
-169.17
- -
- -
14.46
13.38
16.49
17.06
13.66
-0.99
8.57
0.52
0.87
Working Capital
- -
25
23
15
32
266
591
777
1,404
1,560
1,882
1,893
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
26
17
230
242
- -
Total Equity
- -
25
23
16
35
277
650
1,132
1,829
2,014
2,317
2,491
- -
Return on Invested Capital (%)
- -
- -
- -
- -
47.31
31.25
67.98
44.26
27.21
-4.09
12.35
0.66
- -
Return on Capital (%)
- -
- -
- -
- -
77.47
39.04
79.17
51.53
29.63
-2.1
10.93
0.83
- -
Return on Common Equity (%)
- -
-6.35
-7.22
-39.69
77.47
39.04
82.26
53.5
31.05
-1.24
11.58
0.59
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
334
- -
LT Borrowings
- -
224
- -
LT Finance Leases
- -
19
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
55
55
Market Capitalization
1,366
865
1,320

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,514
- -
Cash, Cash Equivalents & STI
- -
146
- -
Accounts Receivable, Net
- -
1,361
- -
Inventories
- -
835
- -
Total Current Liabilities
- -
622
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
334
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
107.71%
33.69%
7.48%
Free Cash Flow
-102.33%
-513.4%
-16.59%
Net Income, GAAP
-48.98%
-265.68%
-94.35%
Sales/Revenue/Turnover
- -
5.3%
-7.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
656
774
733
763
2,926
2026
707
562
725
707
2,702
2027
807
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.17
0.84
0.97
1.56
4.54
2026
0.05
0.04
0.06
0.11
0.26
2027
0.24
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ashish Maheshwari
Full Time Employees
69
Sector
Distribution services
Industry
Medical distributors
Address
MAPS Towers Hyderabad TS India 500096
IPO Date
Nov 30, 2015
Website
balaxipharma.in
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Balaxi Pharmaceuticals Limited is a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of pharmaceutical formulations and bulk drugs. Its product portfolio includes tablets, capsules, injectables, ointments, and syrups across various therapeutic segments such as anti-infectives, analgesics, anti-inflammatory, cardiovascular, and gastrointestinal drugs. The company operates manufacturing facilities complying with regulatory standards and serves markets primarily in India, with an expanding footprint in select international markets. Founded in 1988 and headquartered in Ahmedabad, Gujarat, Balaxi Pharmaceuticals also focuses on research and development for new drug formulations and improving existing ones. In the past 1-2 years, Balaxi Pharmaceuticals has undertaken strategic initiatives including expansions in its manufacturing capabilities and the launch of new product lines to enhance its therapeutic offerings. It has formed partnerships to strengthen its distribution network and improve market penetration. Balaxi has also invested in upgrading technology for better compliance with international quality standards, supporting its ambition to grow in export markets. There have been no recent changes in company name or major restructuring reported. The company continues to focus on innovation, market expansion, and operational efficiency as part of its growth strategy in the pharmaceutical industry. Balaxi operates primarily in the pharmaceutical industry, targeting healthcare providers, hospitals, and retail pharmacies. Its business segments cover generic pharmaceuticals, contract manufacturing, and formulation development. The company is recognized for maintaining compliance with health regulations and pharmaceutical best practices, aiming to deliver quality medicines across various therapeutic areas. Balaxi Pharmaceuticals Limited remains an important player in India’s pharmaceutical sector with evolving plans to broaden its reach and product base. This description incorporates details of Balaxi Pharmaceuticals' core products and services as well as its recent strategic developments and operational focus. It reflects the company’s ongoing commitment to pharmaceutical manufacturing excellence and market growth in India and beyond.